Loading…
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $10M | $-244M | $-251M | $-90M | -1198.6% | 146.7% | - |
| 2024 | $4M | $-123M | $-126M | $-77M | -327.8% | -36.9% | - |
| 2023 | $6M | $-89M | $-96M | $-68M | -80.9% | -76.9% | -438.7% |
| 2022 | $27M | $-62M | $28M | $-70M | 22.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 26.91 | 6.22 | 3.92 | 9.68 |
| Cost Of Revenue | 6.34 | 6.12 | 4.27 | 4.82 |
| Gross Profit | 20.57 | 0.11 | -0.34 | 4.86 |
| Operating Expense | 95.18 | 89.03 | 94.36 | 111.46 |
| Operating Income | -74.61 | -88.92 | -94.70 | -106.60 |
| EBITDA | -62.43 | -89.23 | -123.50 | -243.57 |
| EBIT | -73.19 | -95.89 | -128.02 | -246.77 |
| Pretax Income | -79.97 | -96.36 | -128.03 | -250.64 |
| Tax Provision | -0.19 | -0.46 | -1.79 | 0 |
| Net Income | 28.32 | -95.90 | -126.23 | -250.64 |
| Net Income Common Stockholders | 28.32 | -95.90 | -126.23 | -429.64 |
| Total Expenses | 101.52 | 95.15 | 98.63 | 116.28 |
| Interest Expense | 6.77 | 0.47 | 0.01 | 3.87 |
| Interest Income | 0.13 | 3.24 | 1.42 | 3.21 |
| Research And Development | 47.17 | 48.61 | 53.07 | 41.33 |
| Selling General And Administration | 48.01 | 40.41 | 41.29 | 70.13 |
| Normalized EBITDA | -61.31 | -78.39 | -83.17 | -100.14 |
| Normalized Income | -78.66 | -85.12 | -86.48 | -107.21 |
| Basic EPS | 0.14 | -0.39 | -0.47 | -1.37 |
| Diluted EPS | 0.14 | -0.39 | -0.47 | -1.37 |
| Tax Effect Of Unusual Items | 0 | -0.05 | -0.56 | 0 |
| Tax Rate For Calcs | 0 | 0.01 | 0.01 | 0 |
| Total Unusual Items | -1.12 | -10.84 | -40.32 | -143.43 |
| Total Unusual Items Excluding Goodwill | -1.12 | -10.84 | -40.32 | -143.43 |
| Net Income From Continuing Operation Net Minority Interest | -79.78 | -95.90 | -126.23 | -250.64 |
| Reconciled Depreciation | 10.77 | 6.67 | 4.53 | 3.20 |
| Reconciled Cost Of Revenue | 6.34 | 6.12 | 4.27 | 4.82 |
| Net Interest Income | -6.64 | 2.77 | 1.41 | -0.65 |
| Net Income From Continuing And Discontinued Operation | 28.32 | -95.90 | -126.23 | -250.64 |
| Total Operating Income As Reported | -75.73 | -99.76 | -135.03 | -110.51 |
| Diluted Average Shares | 200.36 | 244.54 | 267.73 | 312.98 |
| Basic Average Shares | 200.36 | 244.54 | 267.73 | 312.98 |
| Diluted NI Availto Com Stockholders | 28.32 | -95.90 | -126.23 | -429.64 |
| Preferred Stock Dividends | 0 | 0 | 0 | 179 |
| Minority Interests | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | 28.32 | -95.90 | -126.23 | -250.64 |
| Net Income Discontinuous Operations | 108.09 | 0 | 0 | 0 |
| Net Income Continuous Operations | -79.78 | -95.90 | -126.23 | -250.64 |
| Other Income Expense | 1.28 | -10.21 | -34.73 | -143.39 |
| Other Non Operating Income Expenses | 1.54 | 0.63 | 5.59 | 0.04 |
| Special Income Charges | -1.12 | -10.84 | -40.32 | -3.91 |
| Write Off | 0 | 0 | 0 | 0 |
| Impairment Of Capital Assets | 1.12 | 10.84 | 40.32 | 3.91 |
| Restructuring And Mergern Acquisition | 0 | 0 | 0 | 0 |
| Earnings From Equity Interest | 0.86 | 0 | 0 | 0 |
| Gain On Sale Of Security | 0 | 0 | 0 | -139.52 |
| Net Non Operating Interest Income Expense | -6.64 | 2.77 | 1.41 | -0.65 |
| Interest Expense Non Operating | 6.77 | 0.47 | 0.01 | 3.87 |
| Interest Income Non Operating | 0.13 | 3.24 | 1.42 | 3.21 |
| Operating Revenue | 26.66 | 6.22 | 3.92 | 9.68 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Precigen, Inc.this co. | PGEN | $1.5B | - | 69.83 | -1198.6% | -14.11 |
| Nuvation Bio Inc. | NUVB | $1.5B | - | 4.92 | -66.9% | -4.95 |
| Harrow, Inc. | HROW | $1.5B | - | 28.56 | -9.9% | 34.30 |
| Intellia Therapeutics, Inc. | NTLA | $1.5B | - | 2.16 | -61.5% | -2.58 |
| Iovance Biotherapeutics, Inc. | IOVA | $1.5B | - | 1.95 |
| -56.0% |
| -3.08 |
| Ardelyx, Inc. | ARDX | $1.5B | - | 8.80 | -36.9% | -38.06 |
| Aveanna Healthcare Holdings Inc. | AVAH | $1.4B | 6.24 | 7.08 | 115.3% | 9.48 |
| Maze Therapeutics, Inc. | MAZE | $1.4B | - | 3.57 | -36.9% | -6.82 |
| Alphatec Holdings, Inc. | ATEC | $1.4B | - | 112.05 | -1153.7% | 95.59 |
| Peer Median | - | 6.24 | 6.00 | -46.5% | -2.83 | |